About the Company
Sutro Biopharma, Inc. is a public biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in January 2009.Sutro's cell-free protein synthesis and site-specific conjugation platform, XpressCF+, contributed to the discovery of STRO-001 and STRO-002, internally-developed antibody drug conjugates, or ADCs. STRO-001 is an ADC targeting CD74, a protein highly expressed in multiple myeloma and non-Hodgkin's lymphoma, and is currently in a Phase I clinical trial. STRO-002 is an ADC targeting folate receptor alpha, a cell-surface protein highly expressed in gynecological cancers. As of 2024 Sutro's drug discovery efforts have focused on antibody-drug conjugates, cytokine-based immuno-oncology therapies, and bispecific antibodies primarily directed at clinically-validated targets for which the current standard of care is suboptimal.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $STRO News
Sutro Biopharma (STRO) Price Target Decreased by 6.45% to 13.15
The average one-year price target for Sutro Biopharma (NasdaqGM:STRO) has been revised to 13.15 / share. This is an decrease ...
What's Going On With Sutro Biopharma (STRO) Stock?
Sutro Biopharma Inc (NASDAQ:STRO) shares are trading lower by 2.8% to $5.18 during Tuesday’s session after the company ...
Sutro Biopharma Inc STRO
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors
Ipsen S.A. partners with Sutro Biopharma, Inc. to develop a pre-clinical antibody drug candidate. Read more on IPSEF and STRO ...
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones
March 25, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates ...
Sutro Biopharma, Inc. (NASDAQ:STRO) Analysts Just Cut Their EPS Forecasts Substantially
The analysts covering Sutro Biopharma, Inc. (NASDAQ:STRO) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for this year.
Sutro Biopharma, Inc. (STRO) Q4 Earnings and Revenues Surpass Estimates
Sutro Biopharma, Inc. (STRO) came out with quarterly earnings of $0.42 per share, beating the Zacks Consensus Estimate of a loss of $0.82 per share. This compares to loss of $0.61 per share a year ...
Sutro Biopharma, Inc. (STRO)
The analysts covering Sutro Biopharma, Inc. ( NASDAQ:STRO ) delivered a dose of negativity to shareholders today, by... SOUTH SAN FRANCISCO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Sutro ...
Sutro Biopharma, Inc.: Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones
March 25, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates ...
STRO Sutro Biopharma, Inc.
Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated ...
Loading the latest forecasts...